Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ANVS
Annovis Bio, Inc.
stock NYSE

Market Open
Jul 30, 2026 12:42:36 PM EDT
1.76USD+2.924%(+0.05)214,636
1.76Bid   1.77Ask   0.01Spread
Pre-market
Jul 27, 2026 8:48:30 AM EDT
1.69USD0.000%(0.00)0
After-hours
Jul 29, 2026 4:49:30 PM EDT
1.69USD-0.924%(-0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
09:11AM EST  Annovis Bio Announces FDA Feedback For Buntanetap Phase 3 Clinical Development In Parkinson's Disease   Benzinga
Dec 20, 2021
08:32AM EST  Annovis Bio CEO Maria Maccecchini Issues Letter To Stockholders   Benzinga
Dec 14, 2021
08:32AM EST  Annovis Bio Announces Publication Of ANVS401 Mechanism Of Action In Peer-Reviewed Pharmaceutics   Benzinga
Dec 9, 2021
09:38PM EST  From Benzinga Global Small Cap Conference: Annovis Bio CEO Now Presenting   Benzinga
Nov 15, 2021
11:13AM EST  Annovis Bio Announces Transfer Of Listing To New York Stock Exchange   Benzinga
Nov 12, 2021
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 9, 2021
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
05:51AM EST  Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday that Number of Alzheimer's Cases Could Triple by 2050   Benzinga
05:50AM EST  Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday   Benzinga
Oct 16, 2021
01:15PM EDT  The Past Week's Notable Insider Buys Included Digitalbridge, Life Time, A SPAC And More   Benzinga
Oct 15, 2021
08:56PM EDT  Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS   PR Newswire
Oct 14, 2021
01:11PM EDT  Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
Oct 13, 2021
10:20AM EDT  Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Annovis   PR Newswire
Oct 12, 2021
10:50PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Oct 11, 2021
10:47PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 8, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 7, 2021
07:45PM EDT  Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS   PR Newswire
06:10PM EDT  CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
Oct 5, 2021
11:24PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
12:23PM EDT  EXCLUSIVE: Annovis Bio CEO Says Co. Planning To Continue Trials For ANVS401 Into Phase 3 For Both Parkinson's And Alzheimer's   Benzinga
12:17PM EDT  EXCLUSIVE: Annovis Bio President & CEO, Maria L. Maccecchini, Ph.D. Now Interviewing On Benzinga's Power Hour Show   Benzinga
10:07AM EDT  EXCLUSIVE: Annovis Bio President & CEO, Maria L. Maccecchini, Ph.D. To Appear On Benzinga's Power Hour Show At 12:15 p.m. EDT   Benzinga
10:02AM EDT  Annovis Bio shares were trading higher after the company announced Phase 2 ANVS401 data for the treatment of Parkinson's disease showed statistically significant improvements in speed and motor function in Parkinson's disease patients.   Benzinga
09:17AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 5, 2021: RIDE, RL, CCXI, ANVS, PROG   Benzinga
07:50AM EDT  EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo   Benzinga
07:50AM EDT  EXCLUSIVE: Annovis Bio Says 'When compared to the placebo group, statistically significant improvements in WAIS coding scores were observed in patients taking ANVS401 5mg, 10mg, 20mg and 80mg once daily'   Benzinga
07:50AM EDT  EXCLUSIVE: Annovis Bio Announces Phase 2 ANVS401 Data For Treatment Of Parkinson's Disease Showing Statistically Significant Improvements In Speed And Motor Function In PD Patients   Benzinga
Oct 4, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:12AM EDT  ANVS Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline   PR Newswire
Oct 1, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 30, 2021
08:25AM EDT  Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP   GlobeNewswire Inc
Sep 29, 2021
09:39PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:23PM EDT  Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS   PR Newswire
Sep 28, 2021
10:25PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Sep 27, 2021
10:54PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 25, 2021
06:24PM EDT  Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Annovis Bio, Inc.   PR Newswire
10:19AM EDT  (ANVS) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel   PR Newswire
Sep 24, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 23, 2021
07:49PM EDT  SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Sep 21, 2021
10:32PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
04:00PM EDT  The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (Annovis) on behalf of those who purchased or acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the Class Period).   GlobeNewswire Inc
Sep 20, 2021
10:48PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 19, 2021
10:33PM EDT  Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS   PR Newswire
Sep 17, 2021
10:00PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 15, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:28PM EDT  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against   PR Newswire
Sep 14, 2021
10:50PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Sep 13, 2021
11:23AM EDT  Pomerantz Law Firm Announces the Filing of a Class Action Against Annovis Bio,   PR Newswire
10:00AM EDT  SLQT, ANVS & VIEW - Bronstein, Gewirtz & Grossman, LLC Reminds   GlobeNewswire Inc
Sep 12, 2021
10:01AM EDT  ANVS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces   GlobeNewswire Inc
Sep 10, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:01AM EDT  Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment   PR Newswire
Sep 9, 2021
08:08PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. (Annovis or the Company) (NYSE: ANVS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 8, 2021
09:42PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 7, 2021
10:38PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Sep 6, 2021
10:23PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 2, 2021
07:13PM EDT  Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP   GlobeNewswire Inc
Sep 1, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 31, 2021
11:02PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Aug 30, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 27, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
03:58PM EDT  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed   PR Newswire
Aug 26, 2021
04:52PM EDT  The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (Annovis) on behalf of those who purchased or acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the Class Period).   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
10:27PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
08:32AM EDT  Annovis Bio To Present At Biomarkers For Alzheimer's Disease Summit 2021 Aug. 26   Benzinga
Aug 23, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 20, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Aug 18, 2021
08:00PM EDT  ANNOVIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm   Business Wire
Aug 3, 2021
08:00PM EDT  ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm   Business Wire
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 30, 2021
09:17AM EDT  PATRIZIA AG To Initiate Conversion Of Company Into Legal Form Of European Company By 2022   RTTNews
Jul 29, 2021
02:30PM EDT  Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Tempur Sealy Shares Spike Higher   Benzinga
12:10PM EDT  Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet   Benzinga
10:26AM EDT  Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
08:32AM EDT  Annovis Bio To Present New Data At 2021 Alzheimer's Association International Conference   Benzinga
Jul 20, 2021
12:32PM EDT  Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022   Benzinga
08:41AM EDT  Annovis Bio Reports Safety Data From Its Phase 2 Alzheimer's Study; Says Data Safety Monitoring Board Has Reviewed Safety And Tolerability Data For Cohort 2 Of Trial And Has Approved Study To Proceed With Cohort 3   Benzinga
Jul 2, 2021
08:32AM EDT  Annovis Bio To Present Data At Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its 2 Phase 2a Trials   Benzinga
Jun 23, 2021
04:44AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 8, 2021
10:41AM EDT  Annovis' Alzheimer's/Parkinson's Candidate Protects Nerve Cells Against Ill Effects of Higher Neurotoxic Proteins   Benzinga
08:31AM EDT  Annovis Bio Announces Prelim. Data Demonstrating ANVS401 'protects certain nerve cells from dying after being infected by gingipains'   Benzinga
Jun 1, 2021
08:32AM EDT  Annovis Bio Highlights Test Result Showing ANVS401 'Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients'   Benzinga
May 24, 2021
06:28AM EDT  A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises   Benzinga
May 23, 2021
06:42PM EDT  Annovis Bio Priced 1M Share Public Offering @$50/Share   Benzinga
May 21, 2021
02:49PM EDT  Mid-Afternoon Market Update: Dow Rises 150 Points; VF Corp Shares Fall On Downbeat Earnings   Benzinga
12:19PM EDT  Mid-Day Market Update: Nasdaq Turns Lower; Annovis Bio Shares Surge   Benzinga
10:22AM EDT  Mid-Morning Market Update: Markets Open Higher; Deere Beats Q2 Estimates   Benzinga
09:07AM EDT  Annovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement   Benzinga
08:06AM EDT  Annovis Announces Results From Double-Blind Placebo-Controlled Study Of ANVS401 Showing Statistically Significant Cognitive Improvement, Measured By Alzheimer's Disease Assessment Scale-Cognitive Subscale 11   Benzinga
May 19, 2021
04:34PM EDT  Annovis Bio Announces Data From Phase 2 Trial Of ANVS401 Showing ' levels of inflammatory markers in PD patients treated with ANVS401 were significantly lower than before treatment.'   Benzinga
May 13, 2021
03:27PM EDT  From BZ Global Small-Cap Conference: Annovis Bio CEO Says Co Has Around $5 Million In The Bank   Benzinga
03:21PM EDT  From BZ Global Small-Cap Conference: Annovis Bio CEO Says Multiple Animal Studies Showed That ANVS401 Improved The Affected Function   Benzinga
03:18PM EDT  From BZ Global Small-Cap Conference: Annovis Bio CEO Says Many Companies Failed To Find The Treatment For Alzheimer's And Parkinson's Disease, But The Company Is On The Good Way To Find The Treatment   Benzinga
03:15PM EDT  From BZ Global Small-Cap Conference: Annovis Bio CEO Says The Co is Developing Drugs To Treat Alzheimer's And Parkinson's Disease   Benzinga
03:12PM EDT  Annovis Bio CEO Begins Presentation During Benzinga's Global Small Cap Conference   Benzinga
08:33AM EDT  Annovis Bio Files For FDA Orphan Drug Designation For ANVS401 In The Treatment Of Alzheimer's Disease In Persons With Down Syndrome   Benzinga
May 6, 2021
06:57AM EDT  Annovis Bio Receives US Patent For Method Of Treating Frontotemporal Dementia And Chronic Traumatic Encephalopathy   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Mar 18, 2021
11:21AM EDT  Annovis Bio Presents Novel Treatment For Alzheimer's And Parkinson's Diseases   Benzinga
Mar 16, 2021
09:24AM EDT  Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination   Benzinga
06:49AM EDT  Annovis Bio Announces Interim Phase 2Data Showing ANVS401 'Improves Speed and Coordination in Parkinson's Patients'   Benzinga
Mar 11, 2021
07:05AM EST  via InvestorWire Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit.   GlobeNewswire Inc
Feb 16, 2021
06:45AM EST  Annovis Bio to Present at the BIO CEO & Investor Digital Conference   GlobeNewswire Inc
Feb 4, 2021
03:07PM EST  Mid-Afternoon Market Update: Dow Surges Over 250 Points; Lannett Shares Plummet   Benzinga
12:19PM EST  Mid-Day Market Update: Gold Down 2.5%; Lizhi Shares Spike Higher   Benzinga
06:49AM EST  Annovis Bio Receives European Patent For Method Of Treating Acute Nerve And Brain Insults   Benzinga
Dec 17, 2020
06:45AM EST  Annovis Bio Interview to Air on Bloomberg International on the   GlobeNewswire Inc
Dec 15, 2020
06:45AM EST  Annovis Bio Showcases its Unique Approach to   GlobeNewswire Inc
Dec 7, 2020
05:22PM EST  Schedule Of NYSE-, Nasdaq-Listed Publicly-Traded Companies Presenting At Benzinga's Small Cap Conference Dec. 8-9   Benzinga
04:05PM EST  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET.   GlobeNewswire Inc
Dec 3, 2020
09:15AM EST  Annovis Bio to Present at the   GlobeNewswire Inc
Nov 16, 2020
09:15AM EST  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium onThursday, November 19, 2020.   GlobeNewswire Inc
Nov 12, 2020
06:45AM EST  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects.   GlobeNewswire Inc
Nov 2, 2020
06:45AM EST  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its Founder and CEO, Maria Maccecchini, Ph.D., is presenting at the Meridian Clinical Trials Summit on November 2, 2020 at 10 a.m. ET.   GlobeNewswire Inc
Oct 29, 2020
07:08AM EDT  Annovis Bio Resumes Treatment Of Patients In Ongoing Phase 2a Study In Alzheimer's Disease   Benzinga
06:45AM EDT  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced it resumed treatment of patients in its Phase 2a clinical trial in early AD patients following the suspension of the trial in March 2020 due to COVID-19.   GlobeNewswire Inc
Oct 22, 2020
06:45AM EDT  Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award   GlobeNewswire Inc
Oct 20, 2020
06:45AM EDT  Annovis Bio CEO Participates in Roundtable Discussion at the   GlobeNewswire Inc
Oct 15, 2020
06:45AM EDT  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its business highlights for the third quarter ended September 30, 2020.   GlobeNewswire Inc
Oct 12, 2020
04:05PM EDT  Annovis Bio to Present at the 2020 BIO Investor Forum   GlobeNewswire Inc
Sep 29, 2020
06:47AM EDT  Annovis Bio Highlights Publication Of ANVS401 Data In Alzheimer's   Benzinga
06:45AM EDT  Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimers Association   GlobeNewswire Inc
Sep 3, 2020
06:45AM EDT  Annovis Bio Interview to Air on Bloomberg International on the   GlobeNewswire Inc
Sep 1, 2020
06:47AM EDT  Annovis Bio Announces Dosing Of First Three Patients In Phase 2a Alzheimer's And Parkinson's Trial   Benzinga
06:45AM EDT  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced dosing of the first three patients in its new Phase 2a clinical trial targeting early AD and PD patients.   GlobeNewswire Inc
Aug 20, 2020
06:46AM EDT  Annovis Bio Actively Recruiting Patients For Its Phase 2a Trials In Alzheimer's And Parkinson's Diseases   Benzinga
06:45AM EDT  Annovis Bio Actively Recruiting Patients for its Phase 2a Trials   GlobeNewswire Inc
Jul 23, 2020
06:45AM EDT  Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announcedits CEO, Maria Maccecchini, Ph.D., will appear on the Executive Leaders Radio program, airing nationally on Radio America (www.radioamerica.org) on July 26, 2020 at 11 a.m. ET.   GlobeNewswire Inc
Jul 20, 2020
06:50AM EDT  Annovis Bio CEO to Present the Company's Approach to Treating Parkinson's Disease at University of Pennsylvania   Benzinga
06:45AM EDT  Annovis Bio CEO to Present the Companys Novel   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC